ruxolitinib,pelabresib
incyte,novartis,MorphoSys
['mpnsm', '#mpn', 'manifest trial']
#eha2023 | francesco passamonti presents the preliminary results of cohort 4 of the manifest trial: pelabresib monotherapy in pts with high-risk essential thrombocythemia who are refractory or intolerant to hu #mpnsm 
Lifting levels of knowledge in myeloproliferative neoplasms (MPN). A global online platform providing latest treatment options and medical information #mpnsm